SEC Filing Analysis: PALISADE BIO, INC. (PALI)

Executive Summary

• Trading Significance: High
• Key Takeaway: A director received a substantial Restricted Stock Unit (RSU) grant equivalent to ~2.0% of the company's total shares outstanding, indicating significant potential future dilution for shareholders.
• Market Impact: Neutral. While the grant is dilutive, this amended filing corrects a previously reported grant that was 8.5 times larger, clarifying the actual compensation and reducing the perceived dilution risk.

Company Information

Field	Value
Company	PALISADE BIO, INC.
Ticker Symbol	PALI
CIK	0001357459
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Williams Donald Allen
CIK	0001620013
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4/A
Transaction Date	2025-10-06
Transaction Code	A (Award)
Security Type	Restricted Stock Units
Shares Involved	182,000
Price Per Share	$0.00
Total Value	$0
Shares Owned After	182,000
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	182,000
% of Shares Outstanding	1.996%
Post-Transaction Ownership	182,000 shares (1.996% of outstanding)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $290 million, this equity grant is significant due to its dilutive effect rather than its immediate dollar value.
• Ownership Concentration: Upon vesting, this grant will give the director a ~2.0% stake in the company, a notable level of ownership for a non-executive director.
• Dilution Impact: The 182,000 shares represent a potential dilution of nearly 2.0% to existing shareholders. This is a material figure that impacts future earnings per share calculations.
• Transaction Significance: The grant is rated 'Highly Significant' because the shares involved exceed the 0.5% threshold of total shares outstanding. The context of this being a major downward correction from a previous filing is also a critical piece of information.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants are a standard form of non-cash compensation. While dilutive, the market may view this filing as a net neutral or slight positive, as it corrects a previously reported grant of 1,538,700 RSUs, which would have represented a much more severe ~16.9% dilution.

Volume & Sentiment

• Expected Volume Impact: Low. RSU grants are compensation-related and do not typically trigger immediate, large-scale trading activity.
• Sentiment Indicator: Neutral. The filing clarifies and reduces uncertainty around executive compensation and potential dilution.

Investment Insights

Positive Market Indicators

• Reporting Correction: The company proactively corrected a significant overstatement in a prior filing, demonstrating responsible financial reporting.

Risk Factors

• Shareholder Dilution: The grant still represents a material ~2.0% potential dilution that will affect existing shareholders' equity value upon vesting over the next three years.

Key Takeaways

1. A director was awarded 182,000 RSUs, representing a significant ~2.0% of the company's outstanding shares.
2. This Form 4/A is an amendment that drastically reduces the grant from a previously filed 1,538,700 RSUs, rescinding the vast majority of the initial award.
3. The transaction's importance stems from its potential dilutive impact, a key metric for a small-cap biotech company like Palisade Bio.

Additional Context

Transaction Notes

• Special Circumstances: This is an amended filing to correct a prior report. The Issuer has rescinded 1,356,700 RSUs of a previously reported grant, leaving the current grant of 182,000 RSUs.
• Vesting Schedule: The RSUs vest in three equal annual installments beginning on the earlier of the 2026 annual meeting or October 6, 2026.